These authors contributed equally to this study.
Dasatinib inhibits mammary tumour development in a genetically engineered mouse model
Article first published online: 9 JUL 2013
Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
The Journal of Pathology
Volume 230, Issue 4, pages 430–440, August 2013
How to Cite
Karim, S. A., Creedon, H., Patel, H., Carragher, N. O., Morton, J. P., Muller, W. J., Evans, T. R., Gusterson, B., Sansom, O. J. and Brunton, V. G. (2013), Dasatinib inhibits mammary tumour development in a genetically engineered mouse model. J. Pathol., 230: 430–440. doi: 10.1002/path.4202
No conflicts of interest were declared.
- Issue published online: 9 JUL 2013
- Article first published online: 9 JUL 2013
- Accepted manuscript online: 24 APR 2013 12:47PM EST
- Manuscript Accepted: 4 APR 2013
- Manuscript Revised: 2 APR 2013
- Manuscript Received: 1 OCT 2012
|path4202-sup-0001-AppendixS1.doc||Word document||33K||Supplementary methods|
|path4202-sup-0002-FigureS1.tif||TIFF image||12242K||Representative haematoxylin and eosin (H&E)-stained section of vehicle- and dasatinib-treated tumours (top panels) and the corresponding pulmonary metastases (bottom panels).|
|path4202-sup-0003-FigureS2.tif||TIFF image||3766K||Heat map displaying the relative abundance of protein levels and post-translational modifications across dasatinib- and vehicle-treated in vivo tumour samples.|
|path4202-sup-0004-TableS1.doc||Word document||40K||Antibodies for reverse-phase protein array analysis.|
|path4202-sup-0005-TableS2.doc||Word document||52K||Location and phenotype of tumours in BLG-Cre, Erbb2KI/+, Ptenfl/+ mice.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.